128 related articles for article (PubMed ID: 19088531)
21. Nail toxicity associated with paclitaxel treatment for ovarian cancer.
Swenson KK; Bell EM; Nissen J
Oncol Nurs Forum; 2013 Jan; 40(1):17-9. PubMed ID: 23269765
[No Abstract] [Full Text] [Related]
22. Scleroderma induced by paclitaxel.
Pedersen JV; Jensen S; Krarup-Hansen A; Riis L
Acta Oncol; 2010 Aug; 49(6):866-8. PubMed ID: 20446892
[No Abstract] [Full Text] [Related]
23. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
[TBL] [Abstract][Full Text] [Related]
24. Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients.
Paulsen T; Marth C; Kaern J; Nustad K; Kristensen GB; Tropé C
Gynecol Oncol; 2000 Mar; 76(3):326-30. PubMed ID: 10684705
[TBL] [Abstract][Full Text] [Related]
25. Taxane associated subacute cutaneous lupus erythematosus.
Marchetti MA; Noland MM; Dillon PM; Greer KE
Dermatol Online J; 2013 Aug; 19(8):19259. PubMed ID: 24021438
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
[TBL] [Abstract][Full Text] [Related]
27. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions.
Micha JP; Goldstein BH; Birk CL; Rettenmaier MA; Brown JV
Gynecol Oncol; 2006 Feb; 100(2):437-8. PubMed ID: 16226797
[TBL] [Abstract][Full Text] [Related]
28. Scleroderma-like cutaneous lesions induced by paclitaxel: a case study.
Kupfer I; Balguerie X; Courville P; Chinet P; Joly P
J Am Acad Dermatol; 2003 Feb; 48(2):279-81. PubMed ID: 12582404
[TBL] [Abstract][Full Text] [Related]
29. Single-dose dexamethasone paclitaxel premedication.
Micha JP; Rettenmaier MA; Dillman R; Fraser P; Birk C; Brown JV
Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
[TBL] [Abstract][Full Text] [Related]
30. Paclitaxel induced systemic lupus erythematosus in a case of cervical carcinoma.
Sanghavi SA; Chikhalkar S; Khopkar US
Indian J Dermatol Venereol Leprol; 2013; 79(4):537-9. PubMed ID: 23760331
[No Abstract] [Full Text] [Related]
31. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination.
de Bree E; Rosing H; Michalakis J; Romanos J; Relakis K; Theodoropoulos PA; Beijnen JH; Georgoulias V; Tsiftsis DD
Eur J Surg Oncol; 2006 Aug; 32(6):666-70. PubMed ID: 16618534
[TBL] [Abstract][Full Text] [Related]
32. Taxanes in ovarian cancer treatment.
Seetalarom K; Kudelka AP; Verschraegen CF; Kavanagh JJ
Curr Opin Obstet Gynecol; 1997 Feb; 9(1):14-20. PubMed ID: 9090476
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel poliglumex for ovarian cancer.
Galic VL; Wright JD; Lewin SN; Herzog TJ
Expert Opin Investig Drugs; 2011 Jun; 20(6):813-21. PubMed ID: 21470062
[TBL] [Abstract][Full Text] [Related]
34. [Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion].
Noda K; Ikeda M; Kudo R; Nishiya I; Yajima A; Tanaka K; Kodama S; Takahashi T; Tokunaga A; Satoh I; Nozawa S; Taketani Y; Terashima Y; Isonishi S; Takeda Y; Nishijima M; Kuroshima Y; Fujii S; Izumi R; Tamaya T; Mori T; Okada H; Ogita S; Ozaki M; Hatae M
Gan To Kagaku Ryoho; 1996 Feb; 23(3):317-25. PubMed ID: 8712825
[TBL] [Abstract][Full Text] [Related]
35. Scleroderma and the taxanes. Is there really a link?
Farrant PB; Mortimer PS; Gore M
Clin Exp Dermatol; 2004 Jul; 29(4):360-2. PubMed ID: 15245529
[TBL] [Abstract][Full Text] [Related]
36. Scleroderma-like cutaneous lesions induced by paclitaxel and carboplatin for ovarian carcinoma, not a single course of carboplatin, but re-induced and worsened by previously administrated paclitaxel.
Konishi Y; Sato H; Sato N; Fujimoto T; Fukuda J; Tanaka T
J Obstet Gynaecol Res; 2010 Jun; 36(3):693-6. PubMed ID: 20598060
[TBL] [Abstract][Full Text] [Related]
37. [A phase II clinical study of China-made paclitaxel in the treatment of cancer patients].
Wu H; Guan Z; Lin T
Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):148-52. PubMed ID: 10920970
[TBL] [Abstract][Full Text] [Related]
38. The relationship between anti-Ro (SS-A) antibody-positive Sjögren's syndrome and anti-Ro (SS-A) antibody-positive lupus erythematosus.
Provost TT; Talal N; Harley JB; Reichlin M; Alexander E
Arch Dermatol; 1988 Jan; 124(1):63-71. PubMed ID: 3257371
[TBL] [Abstract][Full Text] [Related]
39. Cutaneous fibrosis induced by docetaxel: a case report.
Cleveland MG; Ajaikumar BS; Reganti R
Cancer; 2000 Mar; 88(5):1078-81. PubMed ID: 10699898
[TBL] [Abstract][Full Text] [Related]
40. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.
Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M
Gynecol Oncol; 2000 Nov; 79(2):211-5. PubMed ID: 11063646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
